Jacek Olczak, Philip Morris International CEO, joins 'Money Movers' to discuss q2 earnings and smoke-free products.
Breakdown
- Philip Morris International has expanded capacity for Zyn after previous supply constraints. 22s
- Zyn's growth rate has approached 40% following increased supply. 42s
- Regulatory progress, especially with the FDA in the US, remains a key challenge for smoke-free products. 1m 32s
- Philip Morris is pursuing a selective market entry strategy for new products like VIV to ensure compliance and profitability. 3m 17s
- The company is seeing strong volume growth and positive financial impact from its smoke-free product strategy. 3m 53s